Methods and Findings in Experimental
and Clinical Pharmacology
Vol. 25, Suppl. A, 2003
ISSN 0379-0355
Copyright 2003 Prous Science, S.A.
CCC: 0379-0355/2003
http://www.prous.com
General Index
Acamprosate, 130
a1-acid glycoprotein, 167
a1-adrenoceptors, 154
a2-adrenoreceptors, 96, 100, 123
b-adrenoreceptors, 96
Alcoholism, 141
Alprazolam, 100
Alzheimer's disease, 127
Angiotensin II, 101, 104
Animal use, 15, 88
Antiaggregant therapy, 179
Anticholinesterasic inhibitors, 126, 127
Antidepressants, 35, 132, 174
Antiepileptic drugs, 178
Antinociception, 133
Antipsychotic drugs, 29, 51, 174
Anxiolytics, 99
Apoptosis, 125
Aporphine alkaloids, 160
Aspirin, 97
Aspirin/vitamin E, 139, 154
Ayanin, 143
Azoxymethane, 104
Behavioral assays, 51
Benzoldihydroisoquinolines, 120
Bexarotene, 73
b-blockers, 177
Caffeine, 97
Calcium flux, 102
Cannabinoid CB1 receptors, 99, 110, 136
Cannibinoids, 134, 139
Capsaicin, 133
Captopril, 153
l-Carnitine, 147
Caspofungin®, 77
Chlorethylclonidine, 153
Choline, 120
Chondroitin sulfate, 160
Chronic gastric ulcers, 156
Clomethiazole, 173
Colorectal cancer, 104, 118
COMT inhibitors, 128
Corticosterone, 142
COX inhibitors, 156
Curcumin, 117
CYP2C9*3 allele, 166
CYP2D6, 165
Cytochrome P450 CYP2C8, 111
Deferoxamine, 125
Dendrimer-methotrexate, 121
Depression, 3, 25, 96, 122, 123, 142
Dexibuprophen, 155
Dextroamphetamine, 128
Diabetic vasculopathy, 150
Diuretics, 177
DNA-chip technology, 122
Drug development, 43, 45, 47, 49, 51, 51, 53, 57, 59,
61, 63
Drug hypersensitivity, 175, 176
Ebastine, 170, 171
Electrical stimulation, 142
(-)-Epigallocatechin, 149
ERK/MAP-kinase pathway, 134
Erythromycin, 161
Estradiol, 163
Ethanol, 129
Ethinylestradiol, 170
Exocytosis, 112
Flavopiridol, 98
Fluoxetine, 124
Fraxetin, 135
Gabaergic mechanisms, 130
Gabapentin, 138
Gastric mucosal damage, 116
Gastrin, 159
Glatiramer acetate, 71
Glial tumors, 137
Glucomannan, 170
Glucose, 155
Glutamate, 23
Hepatitis, 173
Hepatotoxicity, 173
High throughput screening, 45
Histamine N-methyltransferase, 93
Hormone replacement therapy, 164
5-HT1B receptor, 114
5-HT2A Receptors, 93
Hydralazine, 109, 161
6-Hydroxydopamine, 97
2-Hydroxyoleic acid, 148
Hypergastrinemia, 159
Hypericum extracts, 140, 141
Hypertension, 144, 145, 151, 152, 153, 154, 177
Ibuprofen, 163
Interleukin-1b, 101
Intravesicular pH, 111
Ketorolac, 165
Lead optimization, 49
Lerisetron, 171
Levamisole, 169
Levodopa, 168, 169
Lipid emulsions, 105
Lithium, 124
MDMA (Ecstasy), 131, 132
Melanoma, 119
Methadone, 126, 167
Mineral waters, 159
Molecular modeling, 47
Morphine, 113
Multiple sclerosis, 71
Muscarinic receptors, 92
Nebivolol, 145
Nifedipine, 153
Nitric oxide, 143, 158
Nitric oxide synthase activity, 118
Noradrenergic system, 25
Olanzapine, 122
Opiate addiction, 125, 126
Opioid receptors, 5, 33, 95, 136
Opioids, 112
Oxidative stress, 105, 135, 164
PACAP-38, 156
Pain, 35, 131
Paracetamol, 172, 179
Parkinson's disease, 39, 96
P-Glycoprotein, 167
Pharmacovigilance, 177
Phenanthrene alkaloids, 149, 160
Phenytoin, 116
Phosducin-like protein, 91
Phosphodiesterase 4 inhibitors, 105
Pindolol, 113
Placebo effect, 65
Polymedication, 176, 178
Prazosin, 153
Procalcitonin, 181
Proinflammatory mediators, 119
Proof of concept, 61
Psychiatry, 63, 65
Racecadotril, 75
Reactive oxygen species, 95, 131
Regulatory issue, 67
Reserpine, 94
Resveratrol, 158
Roflumilast, 106
Rosiglitazone, 157
Rutin, 117
S-Adenosylmethionine, 127
Schizophrenia, 3, 23, 79
Seretonergic receptors, 3, 110, 115, 118
Simvastatin, 147, 148
Skin tests, 175
Social pharmacology, 175
Tacrine derivatives, 138
Target validation, 43
Teaching pharmacology, 11, 13, 15, 19, 85, 86, 87, 88, 89
Terazosin, 144
Tetrahydrocannabinol, 96
Thromboprophylaxis, 81
TK 19, 137
Tramadol, 168, 180
2,4,6-Triiodophenol, 172
Triterpenic compounds, 146
Troglitazone, 151
Ultraviolet radiation, 162
Vascular smooth muscle cells, 102
Vegetable oil, 140
Venlafaxine, 180
Virgin olive oil, 162
Voltage-gated calcium channels, 92
Xanthine oxidase, 150
Yeast mutants, 115
Zaprinast, 103
Ziprasidone, 79
Methods and Findings in Experimental and
Clinical Pharmacology Vol. 25, Suppl. A, 2003
ISSN 0379-0355 Copyright 2003 Prous Science, S.A. CCC: 0379-0355/2003 http://www.prous.com